NV Remedies Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: NV Remedies Private Limited Pharmaceutical Export Portfolio Dataset — 15 Products, $4.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

NV Remedies Private Limited — Pharmaceutical Exporter Profile (2026) | 15 Products, $4.8M Trade | TransData Nexus

NV Remedies Private Limited

Indian Pharmaceutical Exporter · Oncology Specialist · $4.8M Total Trade · DGFT Verified

NV Remedies Private Limited is an Indian pharmaceutical exporter with a total trade value of $4.8M across 15 products in 4 therapeutic categories. Based on 158 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Docetaxel ($959.1K), Oxaliplatin ($651.6K), Carboplatin ($550.0K).

NV Remedies Private Limited — Export Portfolio & Destination Treemap

NV Remedies Private Limited pharmaceutical export portfolio — 15 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is NV Remedies Private Limited? — Company Overview & Market Position

NV Remedies Private Limited, established on June 29, 2009, is a private unlisted pharmaceutical company headquartered in Navi Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74900MH2009PTC326499. As of November 20, 2025, NV Remedies reported an authorized capital of ₹1.00 crore and a paid-up capital of ₹0.50 million. The company's registered office is located at Office No. 1001, 1002, 10th Floor, V Times Square Building, Plot No. 3, Sector-15, CBD Belapur, Navi Mumbai, Maharashtra, 400614.

NV Remedies specializes in the development, manufacturing, and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans 15 products across four therapeutic categories, with a significant focus on oncology and antihistamines. In the fiscal year ending March 31, 2024, NV Remedies reported a total export value of $4.8 million USD, encompassing 158 shipments. The top five exported products include Docetaxel, Oxaliplatin, Carboplatin, Paclitaxel, and Chlorpheniramine, collectively accounting for 65.2% of the company's export value.

What Does NV Remedies Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Docetaxel$959.1K

Product Portfolio — Top 15 by Export Value

NV Remedies Private Limited exports 15 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Docetaxel	Oncology	$959.1K	27	2.4%	9
2	Oxaliplatin	Advanced Oncology	$651.6K	16	1.4%	11
3	Carboplatin	Oncology	$550.0K	11	0.8%	5
4	Paclitaxel	Oncology	$550.0K	11	0.7%	14
5	Chlorpheniramine	Antihistamines & Allergy	$441.6K	28	1.0%	15
6	Fluorouracil	Oncology	$400.0K	8	3.3%	5
7	Bleomycin	Advanced Oncology	$290.8K	12	5.2%	4
8	Cisplatin	Oncology	$200.0K	4	1.6%	4
9	Ornidazole	Advanced Antibiotics	$185.5K	10	1.0%	11
10	Cytarabine	Advanced Oncology	$181.6K	9	1.7%	10
11	Etoposide	Oncology	$132.6K	5	1.2%	9
12	Vinorelbine	Advanced Oncology	$101.6K	3	3.0%	5
13	Vincristine	Oncology	$94.6K	7	4.7%	5
14	Dacarbazine	Advanced Oncology	$68.3K	4	4.8%	5
15	Sunitinib	Advanced Oncology	$27.0K	3	0.0%	12

NV Remedies Private Limited exports 15 pharmaceutical products across 4 therapeutic categories with a total export value of $4.8M. The top category is Oncology (59.7% of portfolio), followed by Advanced Oncology (27.3%), indicating a concentrated portfolio with the top 5 products accounting for 65.2% of total export value.

NV Remedies Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

NV Remedies operates manufacturing facilities in India, specializing in the production of finished pharmaceutical formulations. The company emphasizes compliance with international quality standards, ensuring that its products meet the rigorous requirements of both regulated and unregulated markets. While specific details regarding the locations and capacities of these facilities are not publicly disclosed, NV Remedies' commitment to quality is evident in its adherence to Good Manufacturing Practices (GMP) and other relevant certifications.

3Key Leadership

As of November 20, 2025, the board of directors at NV Remedies Private Limited includes:

Raman Kumar Singh – Additional Director, appointed on July 25, 2025.
Iuliia Cherkashyna – Director, appointed on August 10, 2018.
Nitin Jain – Director, appointed on December 2, 2019.

The company's leadership team brings a wealth of experience in the pharmaceutical industry, contributing to NV Remedies' growth and strategic direction.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does NV Remedies Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

NV Remedies Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company focuses on obtaining necessary regulatory approvals to ensure market access in these regions. While specific details regarding regulatory filings and approvals are not publicly disclosed, NV Remedies' commitment to quality and compliance suggests a proactive approach to meeting the stringent requirements of these markets.

2Emerging Markets

NV Remedies has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, including WHO prequalification, facilitates access to these regions. By ensuring that its products meet the rigorous requirements of the World Health Organization, NV Remedies enhances its ability to serve diverse populations in emerging markets.

3Geographic Strategy

NV Remedies demonstrates a diversified geographic strategy by exporting to multiple regions, including the United States, European Union, United Kingdom, Australia, Japan, Africa, Latin America, and Southeast Asia. This approach mitigates concentration risk and positions the company to leverage growth opportunities across various markets. The strategic direction reflects a commitment to global expansion and market diversification.

NV Remedies Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding NV Remedies' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's focus on compliance with international quality standards suggests that it actively pursues necessary regulatory approvals to access markets such as the United States.

2WHO & EU GMP

NV Remedies emphasizes compliance with international quality standards, including Good Manufacturing Practices (GMP) recognized by the World Health Organization (WHO) and the European Union (EU). While specific certifications are not publicly disclosed, the company's commitment to quality assurance and regulatory compliance indicates adherence to these standards.

3CDSCO & Indian Regulatory

NV Remedies operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) are not publicly available.

NV Remedies Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

NV Remedies operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share comparisons are not publicly available, the company's focus on oncology and antihistamines positions it in direct competition with other pharmaceutical exporters specializing in these therapeutic areas. NV Remedies' commitment to quality and regulatory compliance enhances its competitive edge in the global market.

2Key Differentiators

NV Remedies distinguishes itself through its focus on developing proprietary, patented innovations in products and manufacturing processes. This approach secures a competitive edge and enables effective marketing and distribution across global markets. Additionally, the company's comprehensive project management system, encompassing research, development, and technology transfer, ensures successful commercialization of pharmaceutical products.

3Strategic Position

NV Remedies is strategically positioned in the pharmaceutical industry, focusing on the development and export of finished pharmaceutical formulations, including generics and biosimilars. The company's future outlook includes expanding its global footprint, enhancing product offerings, and strengthening partnerships to drive growth and innovation. NV Remedies' commitment to quality and regulatory compliance underpins its strategic direction and market positioning.

Buyer Due Diligence Brief — Evaluating NV Remedies Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

NV Remedies demonstrates a strong track record in the pharmaceutical export sector, with a total export value of $4.8 million USD and 158 shipments across 15 products. The company's portfolio concentration, with the top five products accounting for 65.2% of export value, indicates a focused approach to product offerings. NV Remedies' adherence to international quality standards and regulatory compliance enhances its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering NV Remedies as a supplier:

FDA Registration: Confirm the company's FDA facility registration status through the FDA's official website.
WHO-GMP Certification: Verify WHO Good Manufacturing Practices certification through the World Health Organization's official channels.
EU GMP Certification: Check for EU Good Manufacturing Practices certification via the European Medicines Agency's official resources.

Frequently Asked Questions — NV Remedies Private Limited

How many pharmaceutical products does NV Remedies Private Limited export from India?

NV Remedies Private Limited exports 15 pharmaceutical products across 4 therapeutic categories. The top exports are Docetaxel ($959.1K), Oxaliplatin ($651.6K), Carboplatin ($550.0K), Paclitaxel ($550.0K), Chlorpheniramine ($441.6K). Total export value is $4.8M.

What is NV Remedies Private Limited's total pharmaceutical export value?

NV Remedies Private Limited's total pharmaceutical export value is $4.8M, based on 158 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does NV Remedies Private Limited cover?

NV Remedies Private Limited exports across 4 therapeutic categories. The largest are Oncology (59.7%, 7 products), Advanced Oncology (27.3%, 6 products), Antihistamines & Allergy (9.1%, 1 products).

Get Full NV Remedies Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.